TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8770708

Group type: EXPERIMENTAL
Intervention: Intensive plasma exchange (IPE) or whole blood exchange (WBE) in addition to standard medical therapy
Number of subjects: 8

Group type: COMPARATOR
Intervention: Standard medical therapy
Number of subjects: 8
Study: 2061418

Group type: EXPERIMENTAL
Intervention: Preventive program based on plaque control and topical application of fluoride, with scaling, root planning, and conventional caries therapy; preventive measures recalled every 2-3 months for 6 years, then 1-2 times per year for 9 years, with a subgroup recalled 3-6 times per year.
Number of subjects: 375
Study: 6349652

Group type: EXPERIMENTAL
Intervention: Meclofenamate sodium (300 mg per day for 4 weeks)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 31941416

Group type: EXPERIMENTAL
Intervention: smartphone (SMA)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: video game (VID)
Number of subjects: 25

Group type: COMPARATOR
Intervention: control (CON)
Number of subjects: 25
Study: 30520944

Group type: EXPERIMENTAL
Intervention: Coronary computed tomography angiography (CTA)
Number of subjects: 4415

Group type: EXPERIMENTAL
Intervention: PROMISE-PTP
Number of subjects: 4415
Study: 28403154

Group type: EXPERIMENTAL
Intervention: 56mg/day magnesium cream
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 25
Study: 26284652

Group type: EXPERIMENTAL
Intervention: PHiD‐CV10 vaccine (3 + 1 and 2 + 1 schedules)
Number of subjects: 30527

Group type: EXPERIMENTAL
Intervention: PHiD‐CV10 vaccine (catch-up schedules)
Number of subjects: 30527

Group type: COMPARATOR
Intervention: Hepatitis B or A vaccine (control)
Number of subjects: 30527
Study: 23990567

Group type: EXPERIMENTAL
Intervention: Early ART (initiated immediately)
Number of subjects: 957

Group type: COMPARATOR
Intervention: Standard ART (according to ongoing WHO criteria)
Number of subjects: 957

Group type: EXPERIMENTAL
Intervention: Early ART
Number of subjects: 957
Study: 21136163

Group type: EXPERIMENTAL
Intervention: ACEi/ARB
Number of subjects: 535

Group type: COMPARATOR
Intervention: Other antihypertensive medications
Number of subjects: 535

Group type: COMPARATOR
Intervention: No antihypertensive medications
Number of subjects: 535
Study: 19070525

Group type: EXPERIMENTAL
Intervention: Nitazoxanide (15 mg/kg/day, twice a day for three days)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Probiotics (1 g, twice a day for five days)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Oral rehydration solution (control)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 75
Study: 17579171

Group type: EXPERIMENTAL
Intervention: 64-slice CT planimetry of the aortic valve area
Number of subjects: 36
Study: 15559872

Group type: EXPERIMENTAL
Intervention: Algorithm for ECG analysis
Number of subjects: 22

Group type: COMPARATOR
Intervention: Standard ECG analysis without algorithm
Number of subjects: 22
Study: 11385811

Group type: EXPERIMENTAL
Intervention: Novolizer (breath-actuated multidose dry powder inhaler)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Established inhalational devices (pressurized metered dose inhalers)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novolizer
Number of subjects: 0
Study: 9879160

Group type: EXPERIMENTAL
Intervention: Screening tool for addictive disease
Number of subjects: 52
Study: 7978134

Group type: EXPERIMENTAL
Intervention: Oral midazolam 0.5 mg.kg-1
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 2534744

Group type: EXPERIMENTAL
Intervention: Obese subjects
Number of subjects: 14

Group type: COMPARATOR
Intervention: Reference subjects
Number of subjects: 14
Study: 7952

Group type: EXPERIMENTAL
Intervention: Tolamolol
Number of subjects: 27
Study: 31812949

Group type: EXPERIMENTAL
Intervention: Pressure Pain Threshold (PPT) test on the hand before Cold Pressor Test (CPT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pressure Pain Threshold (PPT) test on the hand during Cold Pressor Test (CPT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pressure Pain Threshold (PPT) test on the hand
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Conditioned Pain Modulation (CPM) test on the hand
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Conditioned Pain Modulation (CPM) test on the face
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Conditioned Pain Modulation (CPM) test on the foot
Number of subjects: 60
Study: 31048584

Group type: EXPERIMENTAL
Intervention: Open fetal repair of myelomeningocele with extended BMI criteria (BMI 35-40)
Number of subjects: 11
Study: 28569553

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Exercise training + electrical myostimulation
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group (exercise training)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Experimental group (exercise training + electrical myostimulation)
Number of subjects: 91
Study: 25693013

Group type: EXPERIMENTAL
Intervention: 3 mg of propranolol per kilogram per day for 6 months
Number of subjects: 460

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Propranolol (successful treatment)
Number of subjects: 460

Group type: COMPARATOR
Intervention: Propranolol and Placebo
Number of subjects: 460
Study: 22118955

Group type: EXPERIMENTAL
Intervention: Quercetin 150 mg/d for 8 weeks
Number of subjects: 49
Study: 21281257

Group type: EXPERIMENTAL
Intervention: 5-hour training program on the VR unit
Number of subjects: 14
Study: 19758254

Group type: EXPERIMENTAL
Intervention: Photodynamic antimicrobial therapy (PACT) with 47 J cm(‐2) of irradiation
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Photodynamic antimicrobial therapy (PACT) with 94 J cm(‐2) of irradiation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group treated with 94 J cm(‐2) of irradiation alone
Number of subjects: 20
Study: 17302913

Group type: EXPERIMENTAL
Intervention: Pulverized candesartan cilexetil
Number of subjects: 21

Group type: COMPARATOR
Intervention: Pulverized irbesartan
Number of subjects: 21

Group type: COMPARATOR
Intervention: Pulverized losartan
Number of subjects: 21

Group type: COMPARATOR
Intervention: Pulverized telmisartan
Number of subjects: 21

Group type: COMPARATOR
Intervention: Pulverized valsartan
Number of subjects: 21
Study: 15339411

Group type: EXPERIMENTAL
Intervention: Zhifang I Decoction
Number of subjects: 46

Group type: COMPARATOR
Intervention: Xuezhikang Capsule
Number of subjects: 46
Study: 11435905

Group type: EXPERIMENTAL
Intervention: Lofepramine and L-phenylalanine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 9555778

Group type: EXPERIMENTAL
Intervention: Transesophageal-guided strategy (TEE) with brief anticoagulation
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Conventional anticoagulation strategy
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Both strategies
Number of subjects: 3000
Study: 7844206

Group type: EXPERIMENTAL
Intervention: Gonadotrophin-releasing hormone agonist (GnRH-a) in a long-term protocol with human menopausal gonadotrophin (HMG)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Gonadotrophin-releasing hormone agonist (GnRH-a) in a short protocol with human menopausal gonadotrophin (HMG)
Number of subjects: 57
Study: 3132484

Group type: EXPERIMENTAL
Intervention: 2000‐mg calcium diet for 8 weeks
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 300‐mg calcium diet for 1, 2, 4, and 8 weeks
Number of subjects: 9
Study: 29808014

Group type: EXPERIMENTAL
Intervention: Ramucirumab
Number of subjects: 0
Study: 27607517

Group type: EXPERIMENTAL
Intervention: NESAP (3.5 mA, 10 Hz)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Sucrose
Number of subjects: 162

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Sucrose plus NESAP
Number of subjects: 162
Study: 24084586

Group type: EXPERIMENTAL
Intervention: DASH diet plus a behavioral weight management intervention (DASH-WM)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: DASH diet alone (DASH-A)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 144
Study: 22388304

Group type: EXPERIMENTAL
Intervention: Nitroglycerin plus diltiazem (200 μg nitroglycerin plus 2.5 mg diltiazem)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Nitroglycerin alone (200 μg nitroglycerin plus placebo)
Number of subjects: 150
Study: 19966092

Group type: EXPERIMENTAL
Intervention: BMI SDS reduction >or=0.5
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: BMI SDS reduction >or=0.25
Number of subjects: 88
Study: 17991690

Group type: EXPERIMENTAL
Intervention: Coping skills intervention for school-age children with type 1 diabetes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Maternal depressive symptoms
Number of subjects: 0
Study: 15665739

Group type: EXPERIMENTAL
Intervention: Sirolimus maintenance therapy after cyclosporine withdrawal
Number of subjects: 4

Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 4
Study: 12164253

Group type: EXPERIMENTAL
Intervention: Extraocular light (11,000 lux)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 10604410

Group type: EXPERIMENTAL
Intervention: Short-chain PA-modified voice prostheses
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Long-chain PA-modified voice prostheses
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (original silicone rubber surfaces)
Number of subjects: 18
Study: 7861018

Group type: EXPERIMENTAL
Intervention: Stavudine at 0.1 mg/kg/day
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Stavudine at 0.5 mg/kg/day
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Stavudine at 2.0 mg/kg/day
Number of subjects: 152
Study: 1953510

Group type: EXPERIMENTAL
Intervention: Flexible dose induction protocol
Number of subjects: 172

Group type: COMPARATOR
Intervention: Empirical treatment by resident medical staff
Number of subjects: 172
Study: 7372069

Group type: EXPERIMENTAL
Intervention: Bismuth subsalicylate therapy
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 31410473

Group type: EXPERIMENTAL
Intervention: Nurse-led care
Number of subjects: 438

Group type: COMPARATOR
Intervention: GP-led care
Number of subjects: 438
Study: 30081106

Group type: EXPERIMENTAL
Intervention: Lower extremity decompression surgery
Number of subjects: 22

Group type: COMPARATOR
Intervention: Observation (control)
Number of subjects: 22
Study: 28193797

Group type: EXPERIMENTAL
Intervention: TMD-VOO
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: TMD-Nuts
Number of subjects: 296

Group type: COMPARATOR
Intervention: Low-fat control diet
Number of subjects: 296
Study: 26223540

Group type: EXPERIMENTAL
Intervention: Home-based HIV testing
Number of subjects: 300
Study: 22336250

Group type: EXPERIMENTAL
Intervention: Propionyl-L-carnitine (PLC) 6g/day
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 21771118

Group type: EXPERIMENTAL
Intervention: Probiotic treatment (n=342)
Number of subjects: 1018

Group type: EXPERIMENTAL
Intervention: Longer duration of exclusive breastfeeding (≥4 vs. <4 months)
Number of subjects: 1018

Group type: COMPARATOR
Intervention: Placebo treatment (n=346)
Number of subjects: 1018
Study: 19947445

Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy (various classes including diuretics, calcium antagonists, ACE inhibitors, and angiotensin II receptor antagonists)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17172556

Group type: EXPERIMENTAL
Intervention: Combined therapy (motor imagery and physical practice)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Physical therapy alone (control group)
Number of subjects: 23
Study: 16382598

Group type: EXPERIMENTAL
Intervention: OptiBond FL (Kerr)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Syntac Classic (Vivadent)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Air abrasion
Number of subjects: 12

Group type: COMPARATOR
Intervention: Polishing
Number of subjects: 12
Study: 12114906

Group type: EXPERIMENTAL
Intervention: Antenatal phenobarbital exposure
Number of subjects: 436

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Intracranial hemorrhage
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: No intracranial hemorrhage
Number of subjects: 436
Study: 9799205

Group type: EXPERIMENTAL
Intervention: ST-segment elevation
Number of subjects: 12142

Group type: COMPARATOR
Intervention: Non-ST-segment elevation
Number of subjects: 12142

Group type: EXPERIMENTAL
Intervention: Non-ST-segment elevation myocardial infarction
Number of subjects: 12142

Group type: COMPARATOR
Intervention: Unstable angina
Number of subjects: 12142
Study: 7696942

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (Sandoglobulin, Sandoz Pharmaceuticals) at a dose of 700 mg/kg for infants weighing 501-1000 g and 900 mg/kg for those weighing 1001-1500 g, repeated every 14 days until 1800 g or discharge/death
Number of subjects: 2416

Group type: COMPARATOR
Intervention: Placebo infusions during phase I (n = 623), no infusion during phase II (n = 589)
Number of subjects: 2416

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 2416
Study: 2577441

Group type: COMPARATOR
Intervention: Chlordesmethyldiazepam 0.1 mg/kg‐1 i.v. (group C)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Sodium thiopental 5 mg/kg‐1 i.v. (Group T)
Number of subjects: 16
Study: 389815

Group type: EXPERIMENTAL
Intervention: Co-trimazine (410 mg sulphadiazine plus 90 mg trimethoprim)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Co-trimoxazole (800 mg sulphamethoxazole plus 160 mg trimethoprim)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Co-trimazine and Co-trimoxazole
Number of subjects: 79
Study: 31912157

Group type: EXPERIMENTAL
Intervention: PEG‐IFN α‐2a for 48 weeks
Number of subjects: 133
Study: 30445572

Group type: EXPERIMENTAL
Intervention: Low suction (-2 cmH2O)
Number of subjects: 228

Group type: COMPARATOR
Intervention: High suction (-10 cmH2O)
Number of subjects: 228
Study: 29074717

Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine-70% isopropyl alcohol (CHX-IA)
Number of subjects: 304
Study: 27515572

Group type: EXPERIMENTAL
Intervention: Cationic emulsion (CE)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Hyaluronate sodium (HS)
Number of subjects: 85
Study: 25151583

Group type: COMPARATOR
Intervention: Orthodontic treatment with premolar extraction (n = 30)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Orthodontic treatment without premolar extraction (n = 34)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Control group, no orthodontic treatment (n = 65)
Number of subjects: 129
Study: 22090280

Group type: EXPERIMENTAL
Intervention: Regular 8-hour night sleep
Number of subjects: 14

Group type: COMPARATOR
Intervention: Continuous wakefulness
Number of subjects: 14
Study: 19617465

Group type: EXPERIMENTAL
Intervention: Golimumab (50 mg or 100 mg every 4 weeks)
Number of subjects: 337
Study: 17877100

Group type: EXPERIMENTAL
Intervention: Hormone status, gynecologic surgery, alcohol intake, age, educational attainment
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Caffeine and fluid intake
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Quality of life measures
Number of subjects: 2
Study: 15195794

Group type: EXPERIMENTAL
Intervention: Self-paced memory training
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Feedback memory training
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Personalized memory training
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Visual presentation memory training
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 26
Study: 11596851

Group type: EXPERIMENTAL
Intervention: Fluphenazine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study: 10023274

Group type: EXPERIMENTAL
Intervention: 8% sevoflurane
Number of subjects: 40

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 40
Study: 7803065

Group type: EXPERIMENTAL
Intervention: Health screening and promotion services offered to experimental group
Number of subjects: 1900

Group type: COMPARATOR
Intervention: Control group (no health screening and promotion services)
Number of subjects: 1900

Group type: EXPERIMENTAL
Intervention: Attendance at health screening services
Number of subjects: 1900
Study: 3289931

Group type: EXPERIMENTAL
Intervention: Diltiazem alone
Number of subjects: 14

Group type: COMPARATOR
Intervention: Digoxin alone
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Combination of diltiazem plus digoxin
Number of subjects: 14
Study: 29793716

Group type: EXPERIMENTAL
Intervention: Blended learning (BL) approach in pharmacy seminar course
Number of subjects: 72
Study: 28267480

Group type: EXPERIMENTAL
Intervention: 80 mg betrixaban
Number of subjects: 2506

Group type: EXPERIMENTAL
Intervention: 40 mg betrixaban
Number of subjects: 2506

Group type: COMPARATOR
Intervention: enoxaparin
Number of subjects: 2506
Study: 26032626

Group type: EXPERIMENTAL
Intervention: LACAeP (Liverpool ADR Causality Assessment e-learning Package)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: LCAT (Liverpool Causality Assessment Tool)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: LACAeP
Number of subjects: 57

Group type: COMPARATOR
Intervention: No training (Control)
Number of subjects: 57
Study: 21736887

Group type: EXPERIMENTAL
Intervention: Acetazolamide (7 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline treatment (control)
Number of subjects: 0
Study: 18426998

Group type: EXPERIMENTAL
Intervention: N(G)‐monomethyl‐l‐arginine (lower dose)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Sildenafil (25 mg PO)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: N(G)‐monomethyl‐l‐arginine (infusion)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Phenylephrine (equipressor doses)
Number of subjects: 14
Study: 16568340

Group type: EXPERIMENTAL
Intervention: Vibration muscle exercise (RVE, 2x6 min daily)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: RVE training
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no RVE)
Number of subjects: 20
Study: 12731640

Group type: EXPERIMENTAL
Intervention: ACTH
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: vigabatrin
Number of subjects: 9

Group type: COMPARATOR
Intervention: Both therapies
Number of subjects: 9
Study: 16084853

Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 10612553

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate (MgSO4) infusion
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control (physiological saline)
Number of subjects: 35
Study: 8565026

Group type: EXPERIMENTAL
Intervention: HCQ 800 mg/d
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 2201541

Group type: EXPERIMENTAL
Intervention: Slow-release carbamazepine (SR) preparation
Number of subjects: 21

Group type: COMPARATOR
Intervention: Conventional carbamazepine (C) preparation
Number of subjects: 21
Study: 7302260

Group type: EXPERIMENTAL
Intervention: 100 mcg 15(R)-15-methyl prostaglandin E2 (PG)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (Pl)
Number of subjects: 40
Study: 31119716

Group type: EXPERIMENTAL
Intervention: LY IGlar
Number of subjects: 493

Group type: COMPARATOR
Intervention: IGlar
Number of subjects: 493
Study: 28865815

Group type: EXPERIMENTAL
Intervention: Anti-inflammatory drugs only (Group A)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Antibiotics for 3 days + anti-inflammatory drugs (Group B)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Single dose of antibiotic 1 hour before extraction + anti-inflammatory drugs (Group C)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Mouthwash for 7 days + anti-inflammatory drugs (Group D)
Number of subjects: 400
Study: 25919834

Group type: EXPERIMENTAL
Intervention: Impaired insight into delusions (assessed using the Delusion Assessment Scale)
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Impaired insight into delusions (assessed after 3 weeks of treatment)
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Impaired insight into delusions (assessed after 6 weeks of treatment)
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Impaired insight into delusions (assessed after 8 weeks of treatment)
Number of subjects: 259
Study: 23562130

Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Exemestane (EXE)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Comparison between TAM and EXE
Number of subjects: 36
Study: 21182118

Group type: EXPERIMENTAL
Intervention: Acupuncture (ACU)
Number of subjects: 0

Group type: COMPARATOR
Intervention: SHAM Acupuncture
Number of subjects: 0
Study: 19609738

Group type: EXPERIMENTAL
Intervention: CRP levels ≥7 mg/L
Number of subjects: 561

Group type: COMPARATOR
Intervention: CRP levels <7 mg/L
Number of subjects: 561

Group type: EXPERIMENTAL
Intervention: Full range of CRP values
Number of subjects: 561
Study: 17511751

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 14734789

Group type: EXPERIMENTAL
Intervention: Individualized homeopathic remedies (LM 1/50,000)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 11497201

Group type: EXPERIMENTAL
Intervention: Malignant Hypertension (MHT)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Uncomplicated nonmalignant essential hypertension (EHT)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 102
Study: 9574454

Group type: EXPERIMENTAL
Intervention: Creatinine clearance (CCr) predicted from plasma creatinine (PCr) and body composition analysis (FFM and BCM) using electrical impedance
Number of subjects: 50

Group type: COMPARATOR
Intervention: Creatinine clearance (CCr) predicted according to the Cockcroft and Gault formula
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional method by collecting 24 h urine
Number of subjects: 50
Study: 7920977

Group type: EXPERIMENTAL
Intervention: Group II (lipid-supplemented solution)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Group I (predominantly carbohydrate solution)
Number of subjects: 26
Study: 30947825

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided injection
Number of subjects: 102

Group type: COMPARATOR
Intervention: Landmark-based injection
Number of subjects: 102